Huakang Biomedical Holdings Company Limited (8622) Stock Statistics & Valuation Metrics

Huakang Biomedical Holdings Company Limited has a market cap or net worth of HK$202.69M. The enterprise value is HK$33.27M.

Huakang Biomedical Holdings Company Limited has 500,472,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Huakang Biomedical Holdings Company Limited’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -8.62%.

The current PE Ratio of Huakang Biomedical Holdings Company Limited is -16.35. Huakang Biomedical Holdings Company Limited’s PEG ratio is 0.78.

In the last 12 months, Huakang Biomedical Holdings Company Limited had revenue of 25.36M and earned -4.16M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -2.82M and capital expenditures 0.00, giving a free cash flow of -2.82M billion.

Huakang Biomedical Holdings Company Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Huakang Biomedical Holdings Company Limited upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.

Huakang Biomedical Holdings Company Limited as a current ratio of 4.90, with Debt / Equity ratio of 0.83%

In the past 12 months, Huakang Biomedical Holdings Company Limited has paid 0.00 in taxes.

Huakang Biomedical Holdings Company Limited EV to EBITDA ratio is -11.89, with an EV/FCF ratio of 0.00.

Huakang Biomedical Holdings Company Limited has HK$36.49M in cash and marketable securities with ¥4.08M in debt, giving a net cash position of -HK$32.41M billion.

Gross margin is 66.77%, with operating margin of -19.76%, and net profit margin of -16.40%.

The average price target for Huakang Biomedical Holdings Company Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―